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Abstract
Introduction Identification of breast cancer patients at risk for
postoperative distant relapse is an important clinical issue.
Existing pathological markers can predict disease recurrence
only to a certain extent, and there is a need for more accurate
predictors.
Methods Using 'counting alleles', a novel experimental method,
we determined allelic status of chromosomes 8p and 18q in a
case-control study with 65 early stage, node negative, invasive
ductal carcinomas (IDCs). The association between allelic
imbalance (AI) of both chromosomal markers and distant
relapses was examined.
Results Eighty percent of tumors contained 8pAI and sixty-eight
percent of tumors contained 18qAI. However, none of the tumor
samples retained both chromosome 8p and 18q alleles. More
importantly, tumors with 8pAI but not 18qAI were more likely to
have distant relapse compared to tumors with 18qAI but not
8pAI.
Conclusion Our finding suggests that differential allelic loss of
chromosomes 8p and 18q may represent subtypes of early
stage IDC with different tumor progression behaviors.
Introduction
Breast cancer is the most frequently diagnosed neoplasia and
the second leading cause of cancer deaths in women world-
wide [1]. The majority of all new breast cancer cases have
early stage tumors without lymph node involvement [2]. Based
on the current clinical and pathological prognostic indicators
such as Tumor-Nodes-Metastases (TNM) staging, HER2/neu
and hormonal receptor status, many early stage breast cancer
patients receive unnecessary adjuvant treatment after the
removal of a primary tumor [3]. As these therapies are associ-
ated with various side effects, identifying those who will be at
a higher risk of distant relapse, and would thus most benefit
from these therapies, is an important issue.
Much of the recent effort in the search for new predictors to
improve prognostic ability has been directed towards the iden-
tification of genetic biomarkers. For example, cytogenetic
studies have shown that the presence of an abnormal chromo-
some complement (aneuploidy) is associated with high tumor
grade and invasive behavior, as well as with eventual disease
progression. As the molecular basis of aneuploidy is allelic
imbalance (AI), many studies have attempted to examine the
association between the AI of individual chromosomes and
disease progression [4]. The results of studies have been
inconsistent, however, partly due to technical problems asso-
ciated with existing methods of AI analysis of clinical speci-
mens [5].
AI = allelic imbalance; CGH = comparative genomic hybridization; CI = confidence interval; IDC = invasive ductal carcinomas; ILC = invasive lobular 
carcinoma; LOH = loss of heterozygosity; OR = odds ratio; PCR = polymerase chain reaction; SNP = single-nucleotide polymorphism; TSG = tumor 
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To address common difficulties associated with the AI analysis
of primary tumors, we have recently developed a technique
called 'counting alleles' that is specifically designed for the
analysis of archived clinical specimens [6,7]. This method is
quantitative and is not susceptible to PCR amplification bias or
DNA degradation. Specifically, allelic status was determined
by evaluating single nucleotide polymorphic (SNP) markers.
Genomic DNA is isolated from archived paraffin-embedded
specimens and diluted to such an extent that single molecules
can be individually amplified in separate PCR reactions; hun-
dreds of PCR reactions were carried out for each specimen
[8]. The detection of different alleles of each SNP locus is car-
ried out with SNP-specific molecular beacons, which were
included in the PCR mixture to allow a single-step reaction
setup [9-11]. Allelic status of a sample is determined quantita-
tively by directly counting the number of each allele in a sam-
ple. Normal tissues and tumors without allelic loss will have
approximately equal counts for both alleles. Tumor samples
with allelic loss but containing normal tissue contamination will
have different counts for each allele. The presence or absence
of AI is determined by a statistical approach called the sequen-
tial probability ratio test, which can determine whether a spe-
cific primary tumor specimen contains AI with up to 50%
normal tissue contamination. The successful application of the
'counting alleles' approach has been demonstrated in studies
of colorectal cancer and prostate cancer [7,12-14]. Here, the
'counting alleles' approach is used to evaluate the risk factors
for disease relapse in early-stage, node-negative breast
cancer.
Materials and methods
Study population
The study population consisted of lymph-node negative breast
cancer patients who had received loco-regional treatment,
consisting of mastectomy or tumorectomy followed by radia-
tion therapy for T1-2N0M0 breast cancer at the University
Hospital Antwerp and the general hospital Saint-Augustinus,
Antwerp, Belgium between 1986 and 1992. These patients
had not received any type of systemic adjuvant therapy (hor-
monal or cytotoxic) and had undergone complete axillary
lymph node dissection for nodal status assessment.
In this case-control study of invasive ductal carcinoma (IDC)
patients, cases were defined as those presenting with distant
radiologically confirmed relapse within five years of initial loco-
regional treatment. Controls were randomly selected from
patients who had no evidence of recurrence after more than
five years based on routine physical examination, yearly mam-
mography, routine biochemical analysis, chest X-ray, annual
liver ultrasound and bone scan. The description of the original
patient selection has been previously published by Colpaert et
al. [15].
Twenty-four cases and forty-one controls who had enough tis-
sue samples for genetic analysis and had IDC were analyzed
in this study. Each patient was assigned a unique identifier,
although no personal identifiers were used in the analysis for
this study. Of the 65 patients, 59 were informative for at least
one polymorphic marker on chromosome 8p, and 59 were
informative for at least one polymorphic marker on chromo-
some 18q.
Data on clinical information and pathologic information were
collected by an oncologist (LD) and a pathologist (CC) at the
hospitals mentioned above. The details of the tumor character-
istics and pathological assessments have been previously
published by Colpaert et al. [15].
DNA purification and 'counting alleles' analysis
A total of 20 sections were cut from each paraffin block for
paired tumor and normal specimens and mounted on non-
coated slides. The first one was cut at 5 microns, stained with
hematoxylin and eosin, and routinely mounted. This section
was used for the identification of tumor and normal cells from
each sample. Sections 2 through 20 were cut at 12 microns
and stained with hematoxylin and eosin; no coverslip was
applied. Regions enriched in tumor cells were microdissected
from these sections, and the normal tissues were also isolated
from the paired normal slides as controls. Microdissected tis-
sue samples were heated at 85°C for 20 minutes in 20 ml of
0.2 M NaOH/1 mM EDTA, and then neutralized with 40 mM
Tris, pH 8.0, 1 mM EDTA (80 ml). The resultant tissue mixtures
were separated in a microcentrifuge for 1 minute at about
12,000 × g and DNA was purified from the supernatants with
a QIAquick Kit (Qiagen, Cat No.28104, Valencia, CA, USA)
The status of chromosome 8p and 18q alleles was determined
using the counting alleles technique [7]. SNP markers on
chromosomes 8p and 18q were retrieved from the National
Center for Biotechnology Information SNP database [16], and
modified from previous studies [13]. Forward and reverse
PCR primers were designed for seven SNPs on chromosome
8p and five SNPs on chromosome 18q. The DNA sequences
of the PCR primers and the molecular beacons have been
reported previously [12]. DNA from the non-neoplastic breast
tissues was used to identify an informative SNP for chromo-
somes 8p and 18q in each patient using digital PCR. Allelic
status analysis was then carried out on both the normal and
tumor DNA. A sequential probability ratio test was used to
determine whether AI was present in the tumor tissue [7]. All
normal DNA tested in this study contained balanced alleles,
and all analyses of AI were performed in a blinded fashion
using coded samples.
Statistical analysis
Χ2 tests and Fisher's exact tests were used to compare clinical
and tumor characteristics and allelic status with early distant
relapse. Association between allelic status and early relapse
was evaluated using unconditional logistic regression with
exact option. All the statistical analysis was carried out usingAvailable online http://breast-cancer-research.com/content/7/6/R1051
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the Statistical Analysis System version 8.2 (SAS Institute,
Cary, NC, USA).
Results
This study focuses on patients with IDC. The mean ages at
diagnosis were 53 years (range 34 to 71 years) for cases and
56 years (range 27 to 78 years) for controls. Forty-six percent
of the cases were pre-menopausal compared to thirty-six per-
cent of the control group (p > 0.05). With regards to tumor
characteristic, the cases and the controls differed significantly
with regards to tumor grade, size, presence of necrosis and
fibrotic foci, and angiogenesis score (Table 1).
AI of chromosomes 8p and 18q was detected in 80% (47/59)
and 68% (40/59), respectively, of the IDCs studied. Individu-
ally, the allelic status of 8p and 18q was not significantly asso-
ciated with distant relapse (Table 2). Combination analysis of
chromosomes 8p and 18q, however, revealed an interesting
finding. We did not identify any tumors retaining both 8p and
18q alleles (8pR/18qR, where R = retention), while the other
combinations of chromosome 18q and 8p allelic statuses
accounted for 20.4% (8pR/18qAI), 35.2% (8pAI/18qR) and
44.4% (8pAI/18qAI) of all tumors (Table 2). Moreover, com-
pared to the 8pR/18qAI group, the 8pAI/18qR group (Odds
Ratio = 9, exact p-value = 0.049, 95% CI: 1.17, 69.47) and
the 8pAI/18qAI group (Odds Ratio = 6, exact p-value = 0.120,
95% CI: 0.76, 47.22) were more likely to be associated with
early distant relapse (Table 2).
Discussion
As we come to recognize the potential limitations of traditional
clinical and pathological predictors for early stage breast can-
cer recurrence, a greater understanding of genetic and molec-
ular pathogenesis is integral to improving diagnosis,
prognosis, and care of breast cancer patients. Studies aimed
at identifying predictors for adjuvant therapy would require
patient populations that are adjuvant-therapy naïve. Current
clinical practice presents a challenge to this, however,
because many patients will have received adjuvant therapy
before their risk for recurrence can be assessed. In this study,
Table 1
Clinical and pathological characteristics in relation to distant relapse
Characteristic Number of patients No distant relapse (n) Distant relapse (n) p-value
Grade
12 7 2 3 4 < 0 . 0 0 1
22 0 1 3 7
31 8 5 1 3
Menopausal status
P r e 2 61 51 1 0 . 4 6
Post 39 26 13
Size
<2 cm 39 29 10 0.02
≥2 cm 26 12 14
Growth pattern
E x p a n s i v e 4 22 41 8 0 . 1 8
Infiltrative 23 17 6
Necrosis
No 50 37 13 <0.001
Yes 15 4 11
Angiogenesis
Chalkey mean low 35 28 7 0.002
Chalkey mean high 30 13 17
Fibrotic focus
No 29 24 5 0.003
Y e s 3 61 71 9
P-values are based on chi-squared test and Fisher's exact test.Breast Cancer Research    Vol 7 No 6    Morikawa et al.
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we had an opportunity to study adjuvant therapy naïve patients
from Belgium and to examine their tumor characteristics and
subsequent disease progression.
Chromosomal instability is the most common alteration seen in
breast cancer. Because chromosomes 8p and 18q are fre-
quently deleted in many solid tumors, we thought to evaluate
the role of 18q and 8p AI in breast cancer carcinogenesis as
these chromosomes could potentially harbor important tumor
suppressor genes (TSGs). Although our original samples con-
sisted of both IDC and invasive lobular carcinoma (ILC), we
limited our samples to IDC as other studies have observed that
IDC and ILC show different profiles in oncogenic amplification
as well as in loss of heterozygosity (LOH) [17,18]. For exam-
ple, a comparative genomic hybridization (CGH) study by
Richard et al. [19] found that the losses of the 16q and 18q
arms were significantly different between IDC and ILC and
suggested that different combinations of genetic alterations
may reflect differences in evolutionary pathways among dis-
tinct morphological subtypes of breast carcinoma.
Nevertheless, there are major obstacles affecting the reliable
application of AI analysis to clinical specimens, including nor-
mal tissue contamination and various degrees of tissue degra-
dation. Conventional methods for AI analysis, such as
microsatellite repeat assay, are not optimally designed for
such tissue types, and may introduce various experimental
biases. The 'counting alleles' method, on the other hand, is
specifically designed for archived, paraffin-embedded sam-
ples, which allows researchers to overcome the problems of
the currently available techniques and significantly enhances
the accuracy of testing for AI in clinical specimens.
Another challenge stems from the characteristics of tumors
themselves. The tumor genome is a dynamic, unstable entity.
Thus, it is conceivable that among the numerous genetic alter-
ations in tumor cells, only a few events lead to the activation of
oncogenes or the inactivation of TSGs, while most are random
and non-specific to tumor development. The limitation of AI
analysis is that allelic loss is not sensitive enough to differenti-
ate between the true inactivation of TSGs and the random loss
of surrogate markers, unless specific locations of TSGs are
determined.
Our analysis of 8p and 18q in IDC resulted in a surprising find-
ing that none of the tumor samples retained both 8p and 18q
alleles. This is in a striking contrast to studies of colorectal and
prostate cancer using the same method [12,13]. In these two
studies, approximately 15% of the tumors retained both alleles
(Table 3). Thus, our findings lead us to hypothesize that the
presence of genetic alterations on 8p or 18q may reflect two
alternative mechanisms of generation of IDC.
We hypothesized that IDC could be classified into two sub-
types based on the critical TSG inactivation on either 18q or
8p (Fig. 1). In addition, we imagined that 18AI/8pAI tumors
represent a mixed group of the two subtypes unable to be
classified by the theoretical limitation of the AI analysis. In fact,
in our analysis, we saw that the 8pAI/18qR group had a higher
frequency of distant relapse compared to the 8pR/18qAI
group, and the frequency for the 8pAI/18AI group fell between
these (Table 2). This phenomenon is unique for IDC because
8pAI/18qAI tumors have the highest risk of recurrence in
colorectal cancer in our previous counting allele study [13].
Moreover, the idea of distinct breast carcinogenesis pathways
represented by specific allelic losses is also consistent with
other CGH and LOH studies, suggesting that there is a pref-
erential combination of genetic alterations. For example, using
CGH analysis, Climent et al. [20] observed that 8p loss is sig-
nificantly associated with 8q gain, and 18q loss is significantly
associated with 20q gain and 9p loss. The association
between 18q loss and 9p loss was also observed by Huiping
et al. [21]. Therefore, 8p and 18q AI do not share a correlation
with the same chromosomal aberrations.
We further thought to address the issue of potential confound-
ers by evaluating the association between the allelic
combination and histopathological characteristics. Tumor
Table 2
Allelic status distribution in relation to distant relapse
Allelic type Number of patients No distant relapse (n) Distant relapse (n) OR p-value 95% CI
8pAI 47 28 19 Referent 0.18a (0.35, 2.83)
8pR 12 10 2 0.29
18qAI 40 28 12 Referent 0.19 (0.59, 7.54)
18qR 19 10 9 2.1
8pR/18qAI 11 10 1 Referent
8pAI/18qR 19 10 9 9.0 0.049a (1.17, 69.47)
8pAI/18qAI 24 15 9 6.0 0.12a (0.76, 47.22)
aP-values based on chi-square test and Fisher's exact test. Approximate 95% confidence intervals (CIs) was calculated for all Odds-ratios. AI, 
allelic imbalance; R, retention (no allelic imbalance); OR, odds ratio.Available online http://breast-cancer-research.com/content/7/6/R1051
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growth type was the only significantly associated factor in our
study population (data not shown). Because the growth type
was not significantly associated with distant relapse in our
data, nor is there much evidence in the current literature to
suggest that it may be a risk factor for distant relapse, only the
crude measure of association is reported. In considering
potential confounders, we recognized that hormonal status is
very important as a prognostic factor of breast cancer. Due to
the regional practice standard at the time the samples were
collected, the receptor status in many of these patients was
not assessed. Nevertheless, we were able to obtain hormonal
status information in about 50% of our samples. In our inform-
ative samples, there was no association between estrogen
receptor status or progesterone receptor status and distant
relapse or the allelic status (data not shown).
What are the putative tumor suppressor genes on 8p and 18q
whose inactivation can lead to the formation of these two dis-
tinct types of IDC? The identification of the TSG on 8p is an
active research area in many laboratories, and linkage studies
in some breast cancer families that do not have BRCA1 and
BRCA2  mutations suggest that 8p12-22 is a candidate
region. Recently, DBC2 (deleted in breast cancer 2) was pro-
posed as the candidate tumor suppressor gene on 8p22
because it was homozygously deleted in two breast tumors,
and its expression was down-regulated in 50% of sporadic pri-
mary breast tumors [22]. More importantly, restoration of its
expression in DBC2-null breast cancer cell lines led to growth
suppression. The biological mechanism of DBC2 function is
still under investigation. MADH4/SAMD4/DPC4 is the best
candidate for the tumor suppressor gene on 18q because it
was homozygously deleted in one out of the eight breast can-
cer cell lines during the initial screening [23]. Even though no
Table 3
Distribution of 8p/18q allelic imbalance combinations among different cancer types
Allelic type IDC CRCa PCAa Exact p-value
cases frequency cases frequency cases frequency
8pR/18qR 0 0% 27 15% 12 14%
8pR/18qAI 10 28.5% 25 14% 18 21% 0.03
8pAI/18qR 10 28.5% 35 19% 19 22%
8pAI/18qAI 15 43% 93 52% 36 42%
aNumber of cases and their frequencies for CRC and PCa are based on data from Zhou et al Lancet 2002, 359:219–225 and Zhou et al The 
Prostate 2004, 61:(1): 81–91. AI, allelic imbalance, R, retention (no allelic imbalance). IDC, Infiltrative ductal carcinoma of breast; CRC, 
adenocarcinoma of colorectal cancer; PCA, adenocarcinoma of prostate cancer,
Figure 1
Hypothetical model of tumor subtypes classified by chromosomal 18q and 8p allelic imbalance (AI) status Hypothetical model of tumor subtypes classified by chromosomal 18q and 8p allelic imbalance (AI) status. Inactivation of tumor suppressor genes 
(TSGs) on either 8p or 18q lead to the formation of two subtypes of invasive ductal carcinoma (IDC) with different risks of distant relapse. Some of 
the AIs are associated with the inactivation of TSGs, whereas others are non-specific events (denoted by asterisks).Breast Cancer Research    Vol 7 No 6    Morikawa et al.
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point mutation was identified in MADH4 during subsequent
screening, immunohistochemistry analysis did indicate that
MADH4  expression is completely absent in some primary
IDCs. Therefore, the genetic/epigenetic inactivation of
MADH4 in IDC requires careful re-evaluation.
In conclusion, we feel that there may be an interesting associ-
ation between LOH of 8p and 18q arms in regards to IDC can-
cer progression. Despite the fact that LOH studies come with
both technical and theoretical challenges, we were able to
address some of those challenges by using a new quantitative
technique to assess a combination of allelic statuses and by
limiting our analysis to a more homogenous group of tumors,
adjuvant therapy naïve, lymph-node negative IDCs. Because of
the relatively small study size, the confidence intervals around
our relative odds ratios are quite wide, indicating a substantial
level of uncertainty. The interpretation of our findings calls for
careful consideration of the study limitations. However, the
detected associations are of sufficient magnitude to warrant
confirmation in larger studies of the role of 8p and 18q in
breast cancer carcinogenesis and progression. If the locations
harboring the specific TSGs can be defined, the two subtypes
of IDC may be better characterized to have different clinical
characteristics and different risks of distant relapse. We thus
hope that this unique finding will serve as a hypothesis gener-
ating platform for further investigations.
Conclusion
The present study used a LOH method that was specifically
designed for archived specimens, and the initial result sug-
gested the possible presence of two subtypes of early stage
IDCs with different potential tumor progression behaviors.
Confirmation of this initial finding with a larger data set could
provide mechanistic insight into the development of IDCs and
may aid the clinical management of patients with IDCs in the
future.
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